SEC Filing Summary: AspenBio Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on October 12, 2012. The registrant is a Colorado-based biopharmaceutical company developing diagnostic tests, specifically the AppyScore blood-based acute appendicitis test. The report addresses a legal development regarding a federal securities class action lawsuit.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal proceedings and does not contain financial performance data.
Material Changes and Legal Proceedings
- Wolfe Suit Background: A class action lawsuit (John Wolfe v. AspenBio Pharma, Inc.) was filed on October 1, 2010, alleging violations of Section 10(b) and Rule 10b-5 of the Exchange Act related to the AppyScore test. The suit covered stock purchases between February 22, 2007, and July 19, 2010.
- Dismissal: On September 13, 2012, the U.S. District Court for the District of Colorado dismissed the lawsuit without prejudice, entering judgment in favor of the Company and individual defendants.
- Appeal Filed: On October 12, 2012, the Plaintiffs filed a Notice of Appeal against the dismissal order.
Outlook, Risks, and Contingencies
The primary contingency identified is the ongoing appeal of the dismissed class action lawsuit. While the lower court ruled in the Company's favor, the filing of the Notice of Appeal indicates the legal dispute remains active. No specific financial guidance or management commentary regarding future operations was included in this filing.
Key Facts for Investor Verification
- Verify the current status of the appeal filed on October 12, 2012, regarding the Wolfe Suit.
- Confirm whether the "without prejudice" dismissal allows for potential refiling of the complaint under different circumstances.
- Review subsequent filings for any updates on the AppyScore test development, as the lawsuit was centered on this product.
- Note that the metadata provided in the request incorrectly identified the company as "Riot Platforms, Inc."; the filing is for AspenBio Pharma, Inc.